Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SWIFT 02: chidamide + CHOP versus placebo + CHOP in previously untreated PTCL-TFH
CTR20251232Phase 3Active
- Sponsor
- Chipscreen Biosciences
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tucidinostat in T-cell lymphoma follicular helper (TFHL), angioimmunoblastic T-cell lymphoma (AITL), follicular T-cell lymphoma (FTCL), sponsored by Chipscreen Biosciences. Started Aug 2025; status: active.
02
Drugs
tucidinostat
03
Conditions
T-cell lymphoma follicular helper (TFHL)angioimmunoblastic T-cell lymphoma (AITL)follicular T-cell lymphoma (FTCL)
Beyond the preview
Go deeper on CTR20251232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251232.